Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/9385
Title: CoMFA analysis of the human beta(1)-adrenoceptor binding affinity of a series of phenoxypropanolamines.
Authors: Louis, Simon N S;Rezmann-Vitti, Linda A;Nero, Tracy L;Iakovidis, Dimitri;Jackman, Graham P;Louis, William J
Affiliation: Department of Medicine, Clinical Pharmacology and Therapeutics Unit, The University of Melbourne, Austin and Repatriation Medical Centre, Heidelberg, 3084 Victoria, Australia
Issue Date: 1-Feb-2002
Citation: European Journal of Medicinal Chemistry; 37(2): 111-25
Abstract: A series of 36 phenoxypropanolamines was examined to determine the structure--activity relationships of beta-adrenoceptor (beta-AR) antagonists for the human beta(1)-AR. The binding affinities of all the compounds were determined for human beta(1)-ARs expressed in Chinese hamster ovary cells and the antagonist potency for rat atrial beta(1)-ARs was determined for 32 of these compounds for comparative purposes. The compounds, based upon a phenoxypropanolamine core structure with various meta-, ortho-, para- and amine-substituents, displayed binding affinities (pK(i)) for the human beta(1)-AR ranging from 5.49 to 9.35. Antagonist potencies (pA(2)) in the rat ranged from 5.52 to 9.56 and correlated with the human binding affinities (r(2)=0.86). Twenty-six compounds were used as the training set for comparative molecular field analysis (CoMFA) of antagonist binding affinity at the human beta(1)-AR and also of antagonist potency for rat atrial beta(1)-ARs. The CoMFA models were derived using both the CoMFA electrostatic and steric field parameters. The initial human beta(1)-AR model (n=26, q(2)=0.59, ONC=6, SE(CV)=0.70, r(2)=0.98, SE(non-CV)=0.16, F(6,19)=148) predicted the binding affinities of seven out of ten test compounds, not included in the training set, with residual pK(i) values less-than-or-equal0.50. The final human beta(1)-AR model (n=36, q(2)=0.66, ONC=5, SE(CV)=0.61, r(2)=0.95, SE(non-CV)=0.24, F(5,30)=107), consisting of the training set plus the test set of compounds, may prove useful in the design of new phenoxypropanolamine type beta(1)-AR antagonists. The initial rat beta(1)-AR model (n=26, q(2)=0.42, ONC=6, SE(CV)=0.76, r(2)=0.94, SE(non-CV)=0.25, F(6,19)=47) predicted the affinities of five out of six test compounds with residual pA(2) values less-than-or-equal0.50. The final rat beta(1)-AR model (i.e. training set plus test set of compounds) (n=32, q(2)=0.38, ONC=5, SE(CV)=0.69, r(2)=0.93, SE(non-CV)=0.24, F(5,26)=67) in particular has a low q(2) value, indicating that, at least for the rat, the biologically active phenoxypropanolamine conformation may be quite different to the low energy extended conformation chosen for this CoMFA study.
Internal ID Number: 11858844
URI: http://ahro.austin.org.au/austinjspui/handle/1/9385
URL: http://www.ncbi.nlm.nih.gov/pubmed/11858844
Type: Journal Article
Subjects: Adrenergic beta-1 Receptor Antagonists
Animals
CHO Cells
Cricetinae
Heart Atria
Humans
Models, Molecular
Molecular Structure
Propanolamines.chemical synthesis.chemistry.metabolism.pharmacology
Rats
Receptors, Adrenergic, beta-1.drug effects.metabolism
Structure-Activity Relationship
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.